Abstract
The cellular protein “Bone marrow stromal antigen 2” (BST2 also called Tetherin, CD317, HM1.24) was identified as a major mediator of the innate immune defense against the dissemination of enveloped viruses. BST2 was shown to physically trap the de novo formed viral particles at the surface of infected cells, thereby reducing viral release. Lentiviruses have evolved specific strategies to down-regulate the expression level of BST2 from the surface of the cells and as such promote viral egress. In Human Immunodeficiency Virus-1 (HIV-1), the accessory protein Vpu counters BST2 antiviral activity. However, the cellular and molecular mechanisms involved are not fully understood. Vpumediated antagonism of BST2 antiviral activity seems to involve complex interplay between the viral protein and host components regulating protein turnover and vesicular trafficking. This review focuses on the interplay between Vpu and the ubiquitin/endosomal pathway in countermeasures of HIV-1 to BST2 restriction, with a particular emphasis on the “Endosomal Sorting Complexes Required for Transport” (ESCRT) machinery.
Keywords: BST2/Tetherin, Vpu, ESCRT, HRS, HIV-1, ubiquitinylation, degradation, cell surface down-regulation, endosome, CD4
Current HIV Research
Title:Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin
Volume: 10 Issue: 4
Author(s): Katy Janvier, Nicolas Roy and Clarisse Berlioz-Torrent
Affiliation:
Keywords: BST2/Tetherin, Vpu, ESCRT, HRS, HIV-1, ubiquitinylation, degradation, cell surface down-regulation, endosome, CD4
Abstract: The cellular protein “Bone marrow stromal antigen 2” (BST2 also called Tetherin, CD317, HM1.24) was identified as a major mediator of the innate immune defense against the dissemination of enveloped viruses. BST2 was shown to physically trap the de novo formed viral particles at the surface of infected cells, thereby reducing viral release. Lentiviruses have evolved specific strategies to down-regulate the expression level of BST2 from the surface of the cells and as such promote viral egress. In Human Immunodeficiency Virus-1 (HIV-1), the accessory protein Vpu counters BST2 antiviral activity. However, the cellular and molecular mechanisms involved are not fully understood. Vpumediated antagonism of BST2 antiviral activity seems to involve complex interplay between the viral protein and host components regulating protein turnover and vesicular trafficking. This review focuses on the interplay between Vpu and the ubiquitin/endosomal pathway in countermeasures of HIV-1 to BST2 restriction, with a particular emphasis on the “Endosomal Sorting Complexes Required for Transport” (ESCRT) machinery.
Export Options
About this article
Cite this article as:
Janvier Katy, Roy Nicolas and Berlioz-Torrent Clarisse, Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin, Current HIV Research 2012; 10 (4) . https://dx.doi.org/10.2174/157016212800792414
DOI https://dx.doi.org/10.2174/157016212800792414 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
microRNA Biogenesis Pathway as a Therapeutic Target for Human Disease and Cancer
Current Pharmaceutical Design Fibroblast Growth Factor-2 Antagonist and Antiangiogenic Activity of Long-Pentraxin 3-Derived Synthetic Peptides
Current Pharmaceutical Design Novel Concepts in the Development of Platinum Antitumour Drugs: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued) Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Muramyl Dipeptide and its Derivatives: Peptide Adjuvant in Immunological Disorders and Cancer Therapy
Current Bioactive Compounds CD133 Expressing Pericytes and Relationship to SDF-1 and CXCR4 in Spinal Cord Injury
Current Neurovascular Research Childhood Solitary Cutaneous Mastocytoma: Clinical Manifestations, Diagnosis, Evaluation, and Management
Current Pediatric Reviews Ewing Sarcoma Family Tumors: Past, Present and Future Prospects
Current Cancer Therapy Reviews Back to the Bench? MEK and ERK Inhibitors for the Treatment of KRAS Mutant Lung Adenocarcinoma
Current Medicinal Chemistry Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Progress in the Research on Naturally Occurring Flavones and Flavonols: An Overview
Current Organic Chemistry Prophylactic Vaccine Strategies and the Potential of Therapeutic Vaccines Against Herpes Simplex Virus
Current Pharmaceutical Design The Hydroxamic Acids as Potential Anticancer and Neuroprotective Agents
Current Medicinal Chemistry Pharmacological Properties of Indazole Derivatives: Recent Developments
Mini-Reviews in Medicinal Chemistry Hydatid Disease: Current Status of Chemotherapy and Drug Delivery Systems
Current Drug Therapy Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Oxidative and Inflammatory Events in Prion Diseases: Can They Be Therapeutic Targets?
Current Aging Science Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry